EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

MAGE-A4 pMHC-targeted CAR-T cells exploiting TCR machinery exhibit significantly improved in vivo function while retaining antigen specificity

Meiou Liu iD, Yasushi Akahori iD, Naoko Imai iD, Linan Wang iD, Kohei Negishi iD, Takuma Kato iD, Hiroshi Fujiwara iD, Hiroshi Miwa iD, Hiroshi Shiku, Yoshihiro Miyahara iD

Journal for ImmunoTherapy of Cancer · 2024

DOI: 10.1136/jitc-2024-010248 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Meiou Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Tsu, Japan. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Immunotherapy, Adoptive, Neoplasm Proteins, Receptors, Antigen, T-Cell. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Science and Technology Agency (JST) SPRING, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The development of chimeric antigen receptor (CAR)-T cell therapies for solid tumors has attracted considerable attention, yet their clinical efficacy remains limited. Therefore, various efforts have been made to improve the efficacy of CAR-T cell therapy. As one promising strategy, incorporating the T-cell receptor (TCR) machinery into CAR structures has been reported to improve the efficacy of CAR-T cells in studies using conventional CARs targeting such as EGFR. However, in the case of peptide/major histocompatibility complex (pMHC)-targeted CARs, the advantages of exploiting TCR machinery have not been fully elucidated. We recently developed MAGE-A4-derived pMHC (MAGE-A4 pMHC)-targeted CAR-T cells (MA-CAR-T cells) using a highly specific human scFv antibody against MAGE-A4 p230-239 /HLA-A*02:01. We aimed to determine whether MAGE-A4 pMHC-targeted CAR-T cells using the TCR machinery (Hybrid MA-TCR-T cells) exhibit superior functionality without compromising antigen specificity.

Methods

We constructed a retroviral vector expressing Hybrid MA-TCR where MAGE-A4 pMHC-specific scFv are fused to human TCR constant chains.

Results

Hybrid MA-TCR-T cells demonstrated superior in vitro functions compared with MA-CAR-T cells, while maintaining strict antigen specificity. In addition, functional superiority of Hybrid MA-TCR-T cells to MA-CAR-T cells became more pronounced on repetitive antigen stimulation. In particular, Hybrid MA-TCR-T cells significantly inhibited tumor growth in an immunodeficient mouse model more effectively than MA-CAR-T cells. Ex vivo analyses indicated that their enhanced therapeutic efficacy might result from higher infiltration of functionally active, less differentiated Hybrid MA-TCR-T cells in tumor tissues.

Conclusions

These findings suggest that leveraging the TCR machinery is a promising strategy for enhancing pMHC-targeted CAR-T cell therapy for solid tumors, potentially leading to more effective treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, NeoplasmImmunotherapy, AdoptiveNeoplasm ProteinsReceptors, Antigen, T-CellHumansMiceAnimalsReceptors, Chimeric AntigenCell Line, TumorXenograft Model Antitumor AssaysNeoplasmsMajor Histocompatibility Complex

Stichwörter der Autor:innen

Adoptive cell therapy - ACTChimeric antigen receptor - CARMajor histocompatibility complex - MHCSolid tumorT cell Receptor - TCR

Substanzen

Antigens, NeoplasmMAGEA4 protein, humanNeoplasm ProteinsReceptors, Antigen, T-CellReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Tsu, Japan.
  • Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan.
  • Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Personalized Cancer Immunotherapy, Mie University Graduate School of Medicine, Tsu, Japan miyahr-y@med.mie-u.ac.jp.

ORCID-Profile: Meiou Liu, Yasushi Akahori, Naoko Imai, Linan Wang, Kohei Negishi, Takuma Kato, Hiroshi Fujiwara, Hiroshi Miwa, Yoshihiro Miyahara

Förderung

  • Japan Science and Technology Agency (JST) SPRING
  • Japan Agency for Medical Research and Development

Zitieren

APA

Liu, M., Akahori, Y., Imai, N., Wang, L., Negishi, K., Kato, T., Fujiwara, H., Miwa, H., Shiku, H., & Miyahara, Y. (2024). MAGE-A4 pMHC-targeted CAR-T cells exploiting TCR machinery exhibit significantly improved in vivo function while retaining antigen specificity. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-010248

Vancouver

Liu M, Akahori Y, Imai N, Wang L, Negishi K, Kato T, et al. MAGE-A4 pMHC-targeted CAR-T cells exploiting TCR machinery exhibit significantly improved in vivo function while retaining antigen specificity. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2024-010248

BibTeX
@article{Liu2024,
  author = {Liu, Meiou and Akahori, Yasushi and Imai, Naoko and Wang, Linan and Negishi, Kohei and Kato, Takuma and Fujiwara, Hiroshi and Miwa, Hiroshi and Shiku, Hiroshi and Miyahara, Yoshihiro},
  title = {MAGE-A4 pMHC-targeted CAR-T cells exploiting TCR machinery exhibit significantly improved in vivo function while retaining antigen specificity},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  doi = {10.1136/jitc-2024-010248}
}
Kostenlos starten →